Accomplished Life Science Executive with Deep Bioprocess Experience NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for biopharmaceutical production, today announced the appointment of Thomas F. Isett to its Board of Directors, effective immediately. Mr. Isett is an accomplished executive …
Texas Meeting Initiates Plan to Bring Economical, Plant-Derived Rituximab to China Market NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan …
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. The first product focus selected pursuant to the Master Joint Development Agreement …